Advertisement
Advertisement
FLNA
F
Filana Therapeutics, Inc. Common Stock
1.91
USDSponsored
-0.09
-4.50%
Mar 18, 16:00 UTC -4
Closed
After-Market
1.91
0.00
-0.26%
FLNA Earnings Reports
Positive Surprise Ratio
No Data Available for FLNA
0%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.31
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/-35.42%
Filana Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 03, 2026, FLNA reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.30 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.31 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oruka Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.45
Surprise
+29.69%
Nektar Therapeutics
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.52
Actual
-$1.78
Surprise
+29.47%
Savara Inc.
Report Date
Mar 13, 2026 For Q4 25
Estimate
-$0.12
Actual
-$0.13
Surprise
-8.15%
Lyell Immunopharma, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.27
Actual
-$7.50
Surprise
-229.53%
Century Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.22
Surprise
+23.88%
Tonix Pharmaceuticals Holding Corp.
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$3.25
Actual
-$3.98
Surprise
-22.32%
Korro Bio, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.10
Actual
-$1.65
Surprise
+21.74%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.46
Surprise
+43.22%
Champions Oncology, Inc.
Report Date
Mar 12, 2026 For Q3 26
Estimate
$0.09
Actual
-$0.02
Surprise
-121.79%
Guardian Pharmacy Services, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.25
Actual
$0.33
Surprise
+29.41%
FAQ
What were Filana Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Filana Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Filana Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Filana Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Filana Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Filana Therapeutics, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement